NCT05899478

Brief Summary

The purpose of this study is to evaluate the effectiveness and safety of the suture-mediated closure system produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd. following endovascular peripheral arterial procedures.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
135

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 5, 2023

Completed
27 days until next milestone

Study Start

First participant enrolled

June 1, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 12, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
Last Updated

June 25, 2025

Status Verified

June 1, 2025

Enrollment Period

7 months

First QC Date

May 5, 2023

Last Update Submit

June 19, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Rate of successful hemostasis

    Calculation method: Patients with successful hemostasis / total cases of subjects in the same group x 100%. Definition of successful hemostasis: Within 10 minutes after completion of the suturing procedure, there is no bleeding or hematoma at the puncture site, and no other intervention or surgical treatment is required.

    10 minutes

Secondary Outcomes (7)

  • Operation time

    Approximately 15-minutes after device removal

  • Hemostasis time

    Approximately 15-minutes after compression

  • Technical success rate

    Approximately 15-minutes after device removal

  • Evaluation of Compatibility with guidewires of the device

    Approximately 15-minutes after device removal

  • Evaluation of Pushing performance of the device

    Approximately 15-minutes after device removal

  • +2 more secondary outcomes

Study Arms (2)

Tyknot® Suture-Mediated Closure System

EXPERIMENTAL

Arterial closure device used is Tyknot® Suture-Mediated Closure System

Device: Tyknot® Suture-Mediated Closure System

Perclose® ProGlide Suture-Mediated Closure System

ACTIVE COMPARATOR

Arterial closure device used is Perclose® ProGlide Suture-Mediated Closure System

Device: Perclose® ProGlide Suture-Mediated Closure System

Interventions

Arterial closure to ensure hemostasis at femoral artery puncture points

Tyknot® Suture-Mediated Closure System

Arterial closure to ensure hemostasis at femoral artery puncture points

Perclose® ProGlide Suture-Mediated Closure System

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18-80
  • Patients who can use 5Fr to 21Fr sheath for common femoral artery puncture for interventional catheterization or therapy
  • Informed consent signed by the patient or legal representative

You may not qualify if:

  • Pregnancy or lactation period;
  • Diameter of femoral artery site for puncture\< 5mm;
  • Have participated in another clinical study during the same period;
  • Known allergy to any device component, and/or contraindications of contrast agents and anticoagulants;
  • Vascular injury at the site of the approach;
  • Groin infection;
  • Morbid obesity (BMI≥40kg / ㎡);
  • Ultrasonographic assessment of the entire common femoral artery wall showed that the common femoral artery stenosis was ≥ 50%;
  • There are femoral aneurysms, arteriovenous fistulas or pseudoaneurysms in the common femoral artery;
  • Clamp vessel closures were used at the previous ipsilateral artery approach;
  • Hematoma at ipsilateral artery approach;
  • Other conditions deemed unsuitable for participation in this clinical trial by the investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

The First Affiliated Hospital of USTC

Hefei, Anhui, 230001, China

Location

Zhongshan Hospital

Shanghai, Shanghai Municipality, 200032, China

Location

Affiliated Hangzhou First People's Hospital ,Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310006, China

Location

The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China

Location

The Fourth Affiliated Hospital ,Zhejiang University School of Medicine

Yiwu, Zhejiang, 322000, China

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 5, 2023

First Posted

June 12, 2023

Study Start

June 1, 2023

Primary Completion

January 1, 2024

Study Completion

April 1, 2024

Last Updated

June 25, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations